[go: up one dir, main page]

MX2013006332A - Composiciones farmaceuticas orales para uso en dislipidemias. - Google Patents

Composiciones farmaceuticas orales para uso en dislipidemias.

Info

Publication number
MX2013006332A
MX2013006332A MX2013006332A MX2013006332A MX2013006332A MX 2013006332 A MX2013006332 A MX 2013006332A MX 2013006332 A MX2013006332 A MX 2013006332A MX 2013006332 A MX2013006332 A MX 2013006332A MX 2013006332 A MX2013006332 A MX 2013006332A
Authority
MX
Mexico
Prior art keywords
oral pharmaceutical
dyslipidemias
pharmaceutical compositions
levels
producing
Prior art date
Application number
MX2013006332A
Other languages
English (en)
Inventor
Gustavo Barranco Hernández
Juan Pablo Senosiain Peláez
Enrique Raúl García-Salgado López
María Del Coral Luna Guiza
Original Assignee
Alparis Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alparis Sa De Cv filed Critical Alparis Sa De Cv
Priority to MX2013006332A priority Critical patent/MX2013006332A/es
Priority to PCT/IB2014/061987 priority patent/WO2014195900A2/es
Publication of MX2013006332A publication Critical patent/MX2013006332A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención comprende una composición farmacéutica oral sólida que contiene una estatina y otro agente antilipidémico, así como un procedimiento para su preparación y el uso de dicha combinación para la elaboración de una formulación farmacéutica útil en el tratamiento de síndrome metabólico, diabetes tipo II, u otras enfermedades. La invención también se refiere al uso de una combinación farmacéutica formada por atorvastatina y fenofibrato, para preparar un medicamento útil para elevar los niveles de HDL2a y HDL2b, y para disminuir los niveles de HDL3a, HDL3b y HDL3c.
MX2013006332A 2013-06-05 2013-06-05 Composiciones farmaceuticas orales para uso en dislipidemias. MX2013006332A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2013006332A MX2013006332A (es) 2013-06-05 2013-06-05 Composiciones farmaceuticas orales para uso en dislipidemias.
PCT/IB2014/061987 WO2014195900A2 (es) 2013-06-05 2014-06-05 Composiciones farmacéuticas orales para uso en dislipidemias

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2013006332A MX2013006332A (es) 2013-06-05 2013-06-05 Composiciones farmaceuticas orales para uso en dislipidemias.

Publications (1)

Publication Number Publication Date
MX2013006332A true MX2013006332A (es) 2014-12-19

Family

ID=52008666

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006332A MX2013006332A (es) 2013-06-05 2013-06-05 Composiciones farmaceuticas orales para uso en dislipidemias.

Country Status (2)

Country Link
MX (1) MX2013006332A (es)
WO (1) WO2014195900A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022071787A1 (es) 2020-09-29 2022-04-07 Laboratorios Silanes S.A. De C.V. Combinaciones farmacéuticas de estatinas y fibratos para el tratamiento y prevención de hiperlipidemias y enfermedades cardiovasculares

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
GR990100388A (el) * 1999-11-09 2001-07-31 Φαρμακευτικος συνδυασμος αποτελουμενος απο χωριστες δοσολογικες μορφες σε συσκευασια συμμορφωσης (compliance package) ενος αναστολεα της αναγωγασης του υδροξυ-μεθυλο-γλουταρυλο συνενζυμου α (στατινης, statin) και ενος παραγωγου του φιμπρικου οξεος....
WO2002024169A1 (en) * 2000-09-20 2002-03-28 Skyepharma Canada Inc. Spray drying process and compositions of fenofibrate
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
CA2555316A1 (en) * 2004-02-09 2005-08-18 Aska Pharmaceutical Co., Ltd. Combined pharmaceutical composition
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
JP2011521992A (ja) * 2008-06-06 2011-07-28 ニコックス エス エイ アトルバスタチン４−（ニトロキシ）ブチルエステルおよび脂質低下剤を含む組成物
WO2011002422A2 (en) * 2009-07-02 2011-01-06 Bilgic Mahmut Solubility enhancing pharmaceutical formulation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022071787A1 (es) 2020-09-29 2022-04-07 Laboratorios Silanes S.A. De C.V. Combinaciones farmacéuticas de estatinas y fibratos para el tratamiento y prevención de hiperlipidemias y enfermedades cardiovasculares

Also Published As

Publication number Publication date
WO2014195900A3 (es) 2015-02-05
WO2014195900A2 (es) 2014-12-11

Similar Documents

Publication Publication Date Title
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
TN2017000554A1 (en) Novel combination for use in the treatment of cancer
MX2015018048A (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
MX340985B (es) Compuestos de n-heteroarilo.
PH12015501913A1 (en) Substituted imidazopyridazines
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
PH12017501133A1 (en) Pyrazolopyridinamines
PH12016500054A1 (en) Substituted pyrazolo-pyridinamines
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
EA201691299A1 (ru) Применение лахинимода для замедления прогрессирования болезни хантингтона
IN2014DN03010A (es)
MX356373B (es) Composiciones que comprenden un agente antibacterial y tazobactam.
MX2013006332A (es) Composiciones farmaceuticas orales para uso en dislipidemias.
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
IN2013MU03428A (es)
EA201591644A1 (ru) Лекарственная форма, содержащая кризотиниб
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines